A Multi-Center, Prospective Single Arm Study to Assess the Efficacy and Safety of RETISERT (Intravitreal Flucinolone Acetonide 0.59mg) in Patients With Refractory Ocular Behcet's Disease

NCT00720928 Phase 4 UNKNOWN

Objectives: To describe the safety and efficacy of intravitreal flucinolone acetonide implants in the management of patients having refractory ocular Behcet's disease Hypothesis: A descriptive observational study Study design: A 1-year, multi-center (including four Korean medical centers) observational study

Details

Lead sponsor	Asan Medical Center
Phase	Phase 4
Status	UNKNOWN
Enrolment	15
Start date	2008-07
Completion	2010-05

Conditions

• Ocular Behcet's Disease,
• Non-Infectious Uveitis
• Refractory Uveitis

Interventions

• flucinolone acetonide

Primary outcomes

• Recurrence in the 36 wks, with one or more of the following events ->2 step Increase in the number of cells in the A/C -2 step increase in the vitreous haze -deterioration in visual acuity — 1 year

Countries

South Korea